Annual Cash & Cash Equivalents
$20.77 M
-$8.21 M-28.32%
December 31, 2023
Summary
- As of February 7, 2025, EVGN annual cash & cash equivalents is $20.77 million, with the most recent change of -$8.21 million (-28.32%) on December 31, 2023.
- During the last 3 years, EVGN annual cash & cash equivalents has fallen by -$25.46 million (-55.07%).
- EVGN annual cash & cash equivalents is now -78.24% below its all-time high of $95.45 million, reached on December 31, 2013.
Performance
EVGN Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$11.32 M
+$1.83 M+19.33%
September 1, 2024
Summary
- As of February 7, 2025, EVGN quarterly cash and cash equivalents is $11.32 million, with the most recent change of +$1.83 million (+19.33%) on September 1, 2024.
- Over the past year, EVGN quarterly cash and cash equivalents has dropped by -$16.01 million (-58.59%).
- EVGN quarterly cash and cash equivalents is now -88.14% below its all-time high of $95.45 million, reached on December 31, 2013.
Performance
EVGN Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
EVGN Cash And Cash Equivalents Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -28.3% | -58.6% |
3 y3 years | -55.1% | -61.0% |
5 y5 years | +257.5% | -63.6% |
EVGN Cash And Cash Equivalents Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | -35.7% | at low | -68.6% | +19.3% |
5 y | 5-year | -55.1% | at low | -75.5% | +19.3% |
alltime | all time | -78.2% | +541.9% | -88.1% | +360.6% |
Evogene Cash And Cash Equivalents History
Date | Annual | Quarterly |
---|---|---|
Sep 2024 | - | $11.32 M(+19.3%) |
Jun 2024 | - | $9.48 M(-20.4%) |
Mar 2024 | - | $11.91 M(-42.6%) |
Dec 2023 | $20.77 M(-28.3%) | $20.77 M(-24.0%) |
Sep 2023 | - | $27.33 M(+35.1%) |
Jun 2023 | - | $20.23 M(-12.0%) |
Mar 2023 | - | $23.00 M(-20.6%) |
Dec 2022 | $28.98 M(-10.3%) | $28.98 M(-9.0%) |
Sep 2022 | - | $31.86 M(+10.4%) |
Jun 2022 | - | $28.87 M(-19.8%) |
Mar 2022 | - | $36.01 M(+11.4%) |
Dec 2021 | $32.33 M(-30.1%) | $32.33 M(-14.1%) |
Sep 2021 | - | $37.63 M(-12.0%) |
Jun 2021 | - | $42.76 M(+10.6%) |
Mar 2021 | - | $38.64 M(-16.4%) |
Dec 2020 | $46.23 M(+33.0%) | $46.23 M(+11.4%) |
Sep 2020 | - | $41.49 M(+33.5%) |
Jun 2020 | - | $31.07 M(-2.9%) |
Mar 2020 | - | $32.01 M(-7.9%) |
Dec 2019 | $34.75 M(+498.1%) | $34.75 M(+111.0%) |
Sep 2019 | - | $16.47 M(+16.8%) |
Jun 2019 | - | $14.10 M(+114.0%) |
Mar 2019 | - | $6.59 M(+13.4%) |
Date | Annual | Quarterly |
---|---|---|
Dec 2018 | $5.81 M(+69.1%) | $5.81 M(+1.8%) |
Sep 2018 | - | $5.71 M(-61.2%) |
Jun 2018 | - | $14.73 M(+175.2%) |
Mar 2018 | - | $5.35 M(+55.8%) |
Dec 2017 | $3.44 M(+6.1%) | $3.44 M(+39.8%) |
Sep 2017 | - | $2.46 M(-57.3%) |
Jun 2017 | - | $5.76 M(+75.0%) |
Mar 2017 | - | $3.29 M(+1.7%) |
Dec 2016 | $3.24 M(-68.3%) | $3.24 M(-40.5%) |
Sep 2016 | - | $5.44 M(-1.7%) |
Jun 2016 | - | $5.53 M(+38.8%) |
Mar 2016 | - | $3.98 M(-61.0%) |
Dec 2015 | $10.22 M(+96.1%) | $10.22 M(-13.7%) |
Sep 2015 | - | $11.85 M(+49.0%) |
Jun 2015 | - | $7.95 M(-21.0%) |
Mar 2015 | - | $10.07 M(+93.1%) |
Dec 2014 | $5.21 M(-94.5%) | $5.21 M(-65.2%) |
Sep 2014 | - | $14.96 M(+71.7%) |
Jun 2014 | - | $8.72 M(-41.3%) |
Mar 2014 | - | $14.86 M(-84.4%) |
Dec 2013 | $95.45 M(+293.4%) | $95.45 M(+473.1%) |
Sep 2013 | - | $16.66 M(-1.4%) |
Jun 2013 | - | $16.88 M(-30.4%) |
Dec 2012 | $24.26 M | $24.26 M |
FAQ
- What is Evogene annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Evogene?
- What is Evogene annual cash & cash equivalents year-on-year change?
- What is Evogene quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Evogene?
- What is Evogene quarterly cash and cash equivalents year-on-year change?
What is Evogene annual cash & cash equivalents?
The current annual cash & cash equivalents of EVGN is $20.77 M
What is the all time high annual cash & cash equivalents for Evogene?
Evogene all-time high annual cash & cash equivalents is $95.45 M
What is Evogene annual cash & cash equivalents year-on-year change?
Over the past year, EVGN annual cash & cash equivalents has changed by -$8.21 M (-28.32%)
What is Evogene quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of EVGN is $11.32 M
What is the all time high quarterly cash and cash equivalents for Evogene?
Evogene all-time high quarterly cash and cash equivalents is $95.45 M
What is Evogene quarterly cash and cash equivalents year-on-year change?
Over the past year, EVGN quarterly cash and cash equivalents has changed by -$16.01 M (-58.59%)